NCT05055167 is a Phase 2 clinical trial of Envafolimab in Non-small Cell Lung Cancer Stage IV, sponsored by The First Affiliated Hospital of Xiamen University.

Who is sponsoring NCT05055167?

NCT05055167 is sponsored by The First Affiliated Hospital of Xiamen University.

What drugs are being tested in NCT05055167?

Interventions in NCT05055167: Envafolimab.

What condition does NCT05055167 study?

NCT05055167 studies Non-small Cell Lung Cancer Stage IV.

Is NCT05055167 still recruiting?

NCT05055167 is currently status unknown. Last updated 24 September 2021.

Last reviewed 2021-09-24 · How we verify

NCT05055167

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC

Status unknown Phase 2 Last updated 24 September 2021

What this trial tests

Phase 2 trial testing Envafolimab in Non-small Cell Lung Cancer Stage IV in 20 participants. Status unknown.

Timeline

30 August 2021

Primary endpoint
30 December 2024

30 June 2025

Quick facts

Lead sponsor	The First Affiliated Hospital of Xiamen University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	30 August 2021
Primary completion	30 December 2024
Estimated completion	30 June 2025
Sites	1 location across China

Drugs / interventions tested

Envafolimab — full drug profile →

Conditions studied

Non-small Cell Lung Cancer Stage IV — all drugs for Non-small Cell Lung Cancer Stage IV →

Sponsor

The First Affiliated Hospital of Xiamen University

Who can join

70 and older, any sex, with Non-small Cell Lung Cancer Stage IV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Explore the efficacy and safety of Envafolimab in first line treatment of elderly patients with locally advanced or metastatic non-small cell lung cancer with high PD-L1 expression, view to providing better treatment options for elderly patients with high PD-L1 expression and improving the survival and prognosis of patients .

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Envafolimab

Trials testing the same drug.

NCT06959693 — A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients Wit · Phase 2, PHASE3 · not yet recruiting
NCT06692491 — Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · Phase 2 · not yet recruiting
NCT07260305 — A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolima · Phase 1 · recruiting
NCT06618391 — Local Injection and Systemic Therapy in the Treatment of NSCLC. · Phase 2 · not yet recruiting
NCT06663007 — RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure · Phase 1, PHASE2 · recruiting

Other recruiting trials for Non-small Cell Lung Cancer Stage IV

Currently open trials in the same condition.

NCT06639191 — [177Lu]Lu-AKIR001 First-in-human Study · EARLY_PHASE1 · recruiting
NCT05818449 — Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation (DigiNet) · NA · active not recruiting

Other The First Affiliated Hospital of Xiamen University trials

Trials by the same sponsor.

NCT06875063 — GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL · Phase 1 · recruiting
NCT07486492 — Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer · EARLY_PHASE1 · not yet recruiting
NCT07458906 — DLL3-Targeted PET/CT in Neuroendocrine Carcinoma · NA · recruiting
NCT07137052 — Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar · not yet recruiting
NCT07189884 — Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05055167 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Xiamen University
Last refreshed: 24 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05055167.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing